SCHEMBL4835517

SCHEMBL4835517

CNCc1cc(F)cc(Cl)c1OC

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.47
SLC6A3 Q01959 3/20 0.47
GAA P10253 1/20 0.47
SLC6A4 P31645 13/20 0.45
HTR2A P28223 11/20 0.45
KCNH2 Q12809 10/20 0.45
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4835664 0.82 GAA (0.42) SLC6A2SLC6A3GAASLC6A4HTR2A
SCHEMBL4832145 0.82 KMT2A (0.62) SLC6A2SLC6A3GAASLC6A4HTR2A
SCHEMBL18589012 0.78 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4HTR2AKCNH2
SCHEMBL3759267 0.77 ALDH1A1 (0.44) GAAKMT2AMEN1SMN1; SMN2
SCHEMBL5273699 0.76 KMT2A (0.38) GAAKMT2ACYP1A2CYP2D6MEN1
SCHEMBL5274054 0.76 TAAR1 (0.53) HTR2ACYP1A2
SCHEMBL4834596 0.76 HTR2A (0.42) SLC6A2SLC6A3GAASLC6A4HTR2A
SCHEMBL5271915 0.76 KMT2A (0.44) GAAHTR2AKMT2ACYP1A2CYP2D6
SCHEMBL4830230 0.76 GAA (0.54) SLC6A2SLC6A3GAASLC6A4HTR2A
SCHEMBL4835197 0.76 GAA (0.46) SLC6A2SLC6A3GAASLC6A4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100467458-C Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB CO LTD (FR) 2009-03-11 CN disclosed
US-7442692-B2 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-10-28 US disclosed
WO-2006103342-A9 INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-10-25 WO disclosed
EP-1707564-B1 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-09-12 EP disclosed
US-20060223830-A1 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-05 US disclosed
WO-2006103342-A2 INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2006-10-05 WO disclosed
EP-1707564-A2 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-10-04 EP disclosed
CN-1840527-A Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2006-10-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223830-A1 Indanyl-piperazine compounds HTR4, NR4A1, NR4A3 SLC6A2 234/4885SLC6A3 172/4885GAA 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.